Poorly differentiated neuroendocrine carcinomas (NECs) of the pancreas are rare malignant neoplasms with a poor prognosis. The aim of this study was to determine the clinicopathologic and genetic features of poorly differentiated NECs and compare them with other types of pancreatic neoplasms. We investigated alterations of KRAS, CDKN2A/p16, TP53, SMAD4/DPC4, DAXX, ATRX, PTEN, Bcl2, and RB1 by immunohistochemistry and/or targeted exomic sequencing in surgically resected specimens of 9 small cell NECs, 10 large cell NECs, and 11 well-differentiated neuroendocrine tumors (PanNETs) of the pancreas. Abnormal immunolabeling patterns of p53 and Rb were frequent (p53, 18 of 19, 95%; Rb, 14 of 19, 74%) in both small cell and large cell NECs, whereas Smad4/ Dpc4, DAXX, and ATRX labeling was intact in virtually all of these same carcinomas. Abnormal immunolabeling of p53 and Rb proteins correlated with intragenic mutations in the TP53 and RB1 genes. In contrast, DAXX and ATRX labeling was lost in 45% of PanNETs, whereas p53 and Rb immunolabeling was intact in these same cases. Overexpression of Bcl-2 protein was observed in all 9 small cell NECs (100%) and in 5 of 10 (50%) large cell NECs compared with only 2 of 11 (18%) PanNETs. Bcl-2 overexpression was significantly correlated with higher mitotic rate and Ki67 labeling index in neoplasms in which it was present. Small cell NECs are genetically similar to large cell NECs, and these genetic changes are distinct from those reported in PanNETs. The finding of Bcl-2 overexpression in poorly differentiated NECs, particularly small cell NEC, suggests that Bcl-2 antagonists/inhibitors may be a viable treatment option for these patients.
N euroendocrine neoplasms of the pancreas are uncommon and represent 1% to 2% of all clinically apparent pancreatic neoplasms. 4 Various proposals regarding the classification and nomenclature of neuroendocrine neoplasms have been put forth, which often differ in the use of specific terminology and criteria for grading and staging. 27, 28 In the 2010 WHO classification, neuroendocrine neoplasms are classified into well-differentiated (low-to-intermediate grade) neuroendocrine tumors (PanNETs) and poorly differentiated (high grade) neuroendocrine carcinomas (NECs) solely on the basis of tumor proliferative rate. 4 Well-differentiated PanNETs are relatively indolent, whereas poorly differentiated NECs are highly aggressive; therapy also differs significantly between these 2 neoplasm categories. 4 The clinicopathologic and genetic features of NECs are, however, largely unknown, leading to inconsistency in their clinical management. 19 Moreover, as small cell NEC of the pancreas is very rare compared with large cell NEC, 9 knowledge of this specific disease entity is mostly derived from case reports.
The origin of poorly differentiated NECs of the pancreas is uncertain. Hypotheses are that they are derived from ductal precursors, from well-differentiated neuroendocrine neoplasms, or de novo. 4, 54 The derivation from pancreatic ductal adenocarcinomas (PDACs) with neuroendocrine differentiation has been suggested and supported by cases with composite conventional ductal adenocarcinoma and high-grade NEC. 17, 35 However, many genetic alterations that characterize PDACs (KRAS, CDKN2A/p16, and SMAD4/DPC4) are not found with any significant frequency in poorly differentiated NECs. 4 Dedifferentiation of well-differentiated PanNETs has also been proposed, 17, 35 although until recently the genetic features of well-differentiated PanNETs were not characterized well enough to allow direct comparisons. However, recent whole-exome sequencing identified several frequently mutated genes in well-differentiated PanNETs, including MEN1, which was mutated in 44.1%, DAXX (death-domain-associated protein) in 25%, ATRX (a-thalassemia/mental retardation syndrome X-linked) in 17.6%, TSC2 in 8.8%, and PTEN in 7.3%. 21 These recent discoveries provide an opportunity to compare the genetic changes in small cell and large cell NEC with these known genetic changes in well-differentiated PanNETs.
In this study we characterized the clinicopathologic features and molecular genetic alterations of surgically resected small cell and large cell NECs of the pancreas and compared them with those of well-differentiated PanNETs. We now show that small cell and large cell NECs are genetically related entities and that the genetic changes in these neoplasms are distinct from those reported in well-differentiated PanNETs.
PATIENTS AND METHODS

Patients
To identify poorly differentiated NECs for study, we conducted a search of the Johns Hopkins Pathology Archives using the term "small cell carcinoma," "large cell carcinoma," or "neuroendocrine carcinoma" and "whipple" or "distal pancreatectomy" spanning January 1, 1988 to July 1, 2010. After the carcinomas derived from the duodenum and common bile ducts were excluded, this search identified 9 patients diagnosed with a primary small cell NEC or large cell NEC of the pancreas. None of the patients showed radiographic evidence of a lung primary by preoperative radiologic examination, or direct invasion from a contiguous site, particularly the ampulla of Vater, on gross examination of the resected surgical specimens. An additional 10 cases of small cell or large cell NECs were taken from the files of the Memorial Sloan-Kettering Cancer Center. In all cases the diagnosis was confirmed by positive immunoreactivity for synaptophysin and/or chromogranin A, as well as for CD56 expression. None of the 9 small cell NECs had shown labeling with antibodies to CD99, a marker for primitive neuroectodermal tumors (data not shown). 36 To compare and contrast the molecular features of poorly differentiated NECs with those of nonfunctioning well-differentiated PanNETs, paraffin-embedded samples of PanNET from 11 patients who had their tumors surgically resected at the Johns Hopkins Hospital or Memorial Sloan-Kettering Cancer Center were also obtained. Approval was obtained from the Institutional Review Boards of both Johns Hopkins and MSKCC for study of all samples used.
The histologic features of all PanNETs and poorly differentiated NECs were reviewed, and each case was also assessed for mitotic indices and Ki67 labeling index. PanNETs were divided into 2 categories: G1, <2 mitoses per 10 HPF and/or r2% Ki67 index; G2, 2 to 20 mitoses per 10 HPF and/or 3% to 20% Ki67 labeling index. 4 NECs were defined by the presence of >20 mitoses per 10 HPF and/or >20% Ki67 labeling index. In cases in which the grade differed for mitotic count compared with Ki67 labeling index, the higher grade was assumed. 4 After review, 2 neoplasms originally diagnosed as large cell NEC of the pancreas in the original pathologic reports at the time of surgery on the basis of abnormal cytologic features and necrosis (patient nos 20 and 21 in Table 1) were reclassified as well-differentiated PanNET, grade 2, because of their mitotic rates of 2 and 3 per 10 HPF and their Ki67 labeling indices of <20%. Poorly differentiated NECs were divided into small cell NECs and large cell NECs, according to the WHO 2010 classification. 4 Specifically, carcinomas with a diffuse, infiltrative growth pattern, small-sized to medium-sized cells with minimal cytoplasm, and fusiform nuclei with finely granular chromatin pattern, inconspicuous nucleoli, and nuclear molding by adjacent nuclei were categorized as small cell NEC (Fig. 1A) . In contrast, carcinomas with a more pronounced nesting pattern, abundant necrosis, and containing neoplastic cells with a moderate amount of amphophilic cytoplasm, large nuclei with coarsely clumped chromatin, and prominent nucleoli were categorized as large cell NEC ( Fig. 1B ).
Immunohistochemistry
Paraffin blocks were cut into sections 4 mm thick for immunolabeling. Antibodies used for immunohistochemical labeling are summarized in Supplemental Digital Content 1 http://links.lww.com/PAS/A106. Reactive small lymphocytes in each case were regarded as internal positive controls for Ki67 and Bcl-2 labeling. Islet cells, stromal cells, and endothelial cells in each case were regarded as internal positive controls for Rb, p16, DAXX, ATRX, Pten, Smad4/Dpc4, synaptophysin, chromogranin A, CD56, Pdx1, and PAX8 labeling. For p53 immunolabeling, scattered acinar cells with nuclear labeling were typically present in the adjacent normal tissue. Therefore, p53 immunolabeling was considered to be "abnormal" when the neoplastic cells either showed a virtual absence of immunolabeling compared with adjacent normal tissue (immunolabeling in <5% of neoplastic cells), suggesting the presence of an intragenic deletion, nonsense, or frameshift mutation ( Fig. 3A) , 32, 40, 50 or showed robust nuclear accumulation of immunolabeled protein in Z30% of neoplastic cells compared with adjacent normal cells ( Fig. 3B ). 2 Negative controls for each of the antibodies were obtained using nonimmune serum instead of the primary antibody.
Sequencing
Seventeen snap-frozen specimens with matched normal tissue corresponding to the Johns Hopkins subset of paraffin-embedded neuroendocrine neoplasms used for immunolabeling (4 small cell NECs, 3 large cell NECs, 11 PanNETs) were obtained from the Johns Hopkins Tumor Bank. The frozen tissue samples were embedded in OCT compound (Sakura Finetek, Tokyo, Japan), sectioned by a cryostat, and stained using hematoxylin and eosin. Tumor tissues were dissected macroscopically or microscopically using a PALM MicroLaser System (Carl Zeiss MicroImaging, Oberkochen, Germany). Genomic DNA from dissected tissues was extracted using phenolchloroform or the QIAmp DNA Micro Kit (Qiagen, Valencia, CA). Genomic DNA from microdissected tissues was quantified by calculating long interspersed nuclear elements by real-time polymerase chain reaction (PCR) as described previously. 53 Whole-genome amplification was performed using 10 ng total template gDNA. PCR amplification was performed using 20 ng of gDNA (macrodissected samples) or whole-genome amplification products (microdissected samples) for KRAS exons 1 and 2, TP53 exons 5 to 9, CDKN2A/p16 exons 1 and 2, and RB1 exons 1 to 25 using intragenic primers flanking these exons (Supplemental Digital Content 2 http://links.lww. com/PAS/A107). PCR products were sequenced using an M13F primer (5 0 -GTAAAACGACGGCCAGT-3 0 ) or M13R primer (5 0 -CAGGAAACAGCTATGACC-3 0 ), which were incorporated into the forward and reverse primer of each primer pair, respectively (Beckman Coulter Genomics, Danvers, MA). Sequencing data were analyzed with sequencher 4.10 software (Gene Codes, Ann Arbor, MI).
Statistics
Frequency distributions were compared using the w 2 test, or a Fisher exact test for sample sizes <5. Continuous variables were compared using an unpaired Student t test. P values of r0.05 were considered statistically significant.
RESULTS
Clinicopathologic Analysis
A total of 19 poorly differentiated NECs were studied, representing 9 small cell NECs and 10 large cell NECs. The clinicopathologic features of these carcinomas are shown in Figure 1 and Table 1 , compared with those of 11 well-differentiated PanNETs. There was no difference in mean age, sex distribution, or tumor location within the pancreas among patients with poorly differentiated NEC versus PanNET, nor was there a difference in these characteristics between patients with small cell versus large cell NEC. Although there was a trend toward larger mean tumor diameter for PanNETs compared with all poorly differentiated NECs, among the poorly differentiated NECs specifically small cell NECs had a significantly larger mean diameter compared with large cell NECs (5.4 ± 2.2 vs. 4.5 ± 1.3 cm, P = 0.04). Poorly differentiated NECs were significantly more likely to have lymph node metastases (P = 0.008) and vessel invasion (P = 0.005) at diagnosis compared with PanNETs. The median postoperative survival for small cell NECs was 14 months (range, 1 to 25 mo) and that for large cell NECs was 10 months (range, 1 to 104 mo). Information regarding adjuvant treatment was available for 14 of 19 patients with poorly differentiated NEC, indicating that a subset received either etoposide/cisplatin or irinotecan/ cisplatin, the standard therapy for patients with small cell lung carcinoma. 30, 39 
Immunohistochemical Analyses
The results of immunohistochemical labeling are summarized in Table 2 . Poorly differentiated NECs exhibited a high proliferative rate as assessed by Ki67 labeling, with a mean labeling index of 51.4%. Among poorly differentiated NECs, small cell NEC showed a significantly higher mean labeling index compared with large cell NEC (60.4% vs. 43.4%, P = 0.02). Mitotic counts generally correlated with Ki67 labeling indices; however, there was no difference in the mean mitotic counts between these 2 groups (40.9 ± 13.6 vs. 34.3 ± 19.5).
The diagnosis of neuroendocrine differentiation was confirmed in these cases by positive immunoreactivity for synaptophysin, chromogranin A, and CD56 (data not shown), and there was no significant difference in the frequency or labeling patterns between small cell NEC, large cell NEC, and well-differentiated PanNET for these markers. Next, we performed immunolabeling for DAXX, ATRX, and Pten, 3 of the 5 genes that undergo somatic alteration in well-differentiated PanNETs. 21 In that study, loss of immunolabeling for each protein correlated with an intragenic mutation or deletion of the respective gene. 21, 56 All 9 small cell NECs and all 10 large cell NECs immunolabeled for nuclear DAXX and ATRX (Figs. 2A, C), whereas 1 (9.1%) and 4 (36.4%) of the 11 well-differentiated PanNETs had loss of nuclear DAXX and ATRX immunolabeling, respectively (Figs. 2B, D). Loss of DAXX and ATRX labeling was mutually exclusive, and thus a total of 5 of 11 (45%) PanNETs showed loss of this cellular pathway similar to that reported by Jiao et al. 21 Pten expression was lost in 1 of 9 (11%) small cell NECs and in none of 10 large cell NECs or 11 well-differentiated PanNETs.
Pdx1 [pancreatic duodenal homeobox (1)] is a homeodomain transcription factor with critical regulatory roles in early pancreas development 42 and is used as a pancreatic lineage marker. 13, 45 Two of 8 (25%) available sections of small cell NECs and 4 of 10 (40%) large cell NECs immunolabeled for Pdx1, whereas Pdx1 expression was seen in 8 of 9 (88.9%) well-differentiated PanNETs. PAX (paired box) 8, also a transcription factor recently reported to be frequently expressed in well-differentiated PanNETs, 31, 48 was expressed in 4 of 9 (44%) small cell NECs, 5 of 10 (50%) large cell NECs, and 6 of 11 (54.5%) well-differentiated PanNETs.
Abnormal immunolabeling for p53 was detected in all 9 (100%) small cell NECs and in 9 of 10 (90%) large cell NECs (Figs. 3A, B ), whereas none of 11 well-differentiated PanNETs showed abnormal labeling for p53. Similarly, Rb protein expression was lost in 8 of 9 (88.9%) small cell NECs (Fig. 3C ) and in 6 of 10 (60%) large cell NECs. It is interesting to note that all 5 NECs (1 small cell NEC and 4 large cell NECs) with retention of Rb protein expression showed loss of p16 labeling (Fig. 4) , indicating that Rb and p16 loss is mutually exclusive in poorly differentiated NECs and that virtually all poorly differentiated NECs have disruption of the Rb/p16 cell cycle pathway. In contrast, positive immunolabeling for Rb and p16 was observed in all well-differentiated PanNETs analyzed. Abnormal immunolabeling for p53 and/or Rb/p16 was robustly associated with a mitotic rate and Ki67 labeling index of >20% (P = 0.000001). Finally, we immunolabeled all neuroendocrine neoplasms for Smad4/Dpc4, which serves as a robust marker of SMAD4/DPC4 genetic status and is lost in 55% of PDACs. Loss of Smad4/Dpc4 labeling was seen in none of 9 small cell NECs, 1 of 10 (10%) large cell NECs, and in none of 11 well-differentiated PanNETs, indicating that inactivation of the SMAD4/DPC4 gene is a rare event in neuroendocrine neoplasms.
Overexpression of Bcl-2 protein was observed in all 9 (100%) small cell NECs (Fig. 3D ), in 5 of 10 (50%) large cell NECs, and in 2 of 5 (40%) intermediate-grade welldifferentiated PanNETs (G2) immunolabeled for Bcl-2. It is noteworthy that these 2 intermediate-grade well-differentiated PanNETs (G2) showing overexpression of Bcl-2 protein were originally diagnosed as large cell NEC of the pancreas on the basis of morphologic features, despite their relatively lower Ki67 labeling index and mitotic rates ( Table 2 ). In contrast, none of 6 low-grade well-differ- entiated PanNETs (G1) immunolabeled for Bcl-2. Among all neoplasms studied, positive labeling for Bcl-2 was significantly associated with both a higher mitotic rate (P = 0.0002) and Ki67 labeling index (P = 0.0001), and this relationship persisted when analyzed specifically among poorly differentiated NECs and well-differentiated PanNETs ( Table 3 ).
Genetic Analysis
To determine whether genetic alterations of the TP53, RB1, or CDKN2A/p16 genes underlie the observed immunolabeling patterns seen in poorly differentiated NECs, we Sanger sequenced the TP53, RB1, and CDKN2A/p16 genes in snap-frozen samples of 4 small cell NECs, 3 large cell NECs, and 11 well-differentiated PanNETs (G2, 4 cases; and G1, 7 cases). Activating mutations in KRAS, present in virtually all PDACs, were also assessed.
The results of sequencing efforts are summarized in Table 4 . An activating KRAS gene mutation was identified in 2 of 7 poorly differentiated NECs, corresponding to 1 of 4 small cell NECs and 1 of 3 large cell NECs. One of these KRAS mutations was a rare homozygous dinucleotide point mutation identified at codon 12 (glycine to leucine, GGT to CTT). 11 Inactivating mutations in the TP53 gene were identified in 4 of 7 poorly differentiated NECs, corresponding to 2 small cell NECs and 2 large cell NECs. Two of these mutations were nonsense mutations (p.E307X and p.R196X) predicted to result in loss of expression, and by immunolabeling both of these carcinomas showed complete absence of p53 labeling. In contrast, the remaining 2 mutations were missense mutations (p.S127T and p.V216L) (Fig. 5) , and by immunolabeling both of these carcinomas showed a robust nuclear accumulation of p53 protein. None of the 11 well-differentiated PanNETs harbored a mutation in TP53 consistent with both normal immunolabeling patterns and exomic sequencing of these lesions. 21 Inactivating mutations in the RB1 gene were identified in 5 poorly differentiated NECs corresponding to 3 of 4 (75%) small cell NECs and 2 of 3 (66.7%) large cell NECs; of these, 2 were splice site mutations (c.861-2T>A and c.1219-2A>G) (Fig. 5) , and 3 were frameshift mutations (c.803_804del, c.868_869insA, and c.2237_2251del). All 5 NECs with an RB1 mutation showed complete absence of immunolabeling. Again, none of the 11 well-differentiated PanNETs of the pancreas showed a mutation in RB1 consistent with immunolabeling data and previous exomic sequencing. 21 No CDKN2A/p16 mutations were observed in the 4 small cell NECs or 3 large cell NECs, nor were they seen in 11 well-differentiated PanNETs.
DISCUSSION
Poorly differentiated NECs are uncommon neoplasms; among these small cell NEC of the pancreas is extremely rare. We therefore examined the clinicopathologic, immunohistochemical, and genetic features of a series of small cell and large cell NECs and compared them with those of well-differentiated PanNETs. Consistent with previous reports, poorly differentiated NEC occurred most often in the head of the pancreas. 47 Moreover, the poorly differentiated NECs in the current study had aggressive biological behaviors, featuring vascular invasion (94%), perineural invasion (69%), and lymph node metastases (88%). However, 11 of 18 (61%) patients with available information survived over 12 months (median survival 13 mo), conceivably because this study focused on a group of highly selected patients with limited disease at diagnosis and who were able to undergo surgical resection. In contrast, most cases reported in the literature were diagnosed at an advanced stage of disease, and their overall survival varied between 1 and 12 months. 7, 25 Our data suggest that small cell and large cell NECs are genetically related entities. Abnormal immunolabeling for p53 and the Rb/p16 pathways was detected in virtually all small cell and large cell NECs but not in any PanNETs, indicating that coinactivation of these 2 pathways is a fundamental genetic feature of poorly differentiated NEC. Moreover, loss of Rb protein was mutually exclusive with loss of p16 protein, in keeping with the close relationship of these protein products in cell cycle regulation. 41 Sequencing analyses of poorly differentiated NECs indicated that intragenic mutation is the major mechanism underlying loss of p53 and Rb protein expression. In contrast, genetic inactivation of RB1 is reported to be an uncommon event in both PDACs and PanNETs. 3, 8, 14 In relation to this finding, inactivating mutations in DAXX and ATRX were exclusively found in PanNETs but not in small cell or large cell NECs. Although this finding may support the notion that NEC is a genetically distinct entity from well-differentiated PanNET, it does not fully rule out the possibility that some well-differentiated PanNETs may transform genetically into poorly differentiated NECs. 17 This hypothesis is only indirectly supported by their shared expression of generic neuroendocrine cell markers and by the presence in both tumor cell types of small dense-core granules of neuroendocrine caliber. However, Ordonez et al 43 reported that ultrastructural features may serve to separate NECs of the pancreas from well-differentiated PanNETs in which the granules are distinctly larger and are distributed throughout the cytoplasm and in which dendritic processes are not usually seen. Moreover, Jiao et al 21 reported that patients with well-differentiated PanNETs that did not have DAXX/ATRX mutations survived for a significantly shorter period of time compared with patients with these mutations, suggesting that PanNETs without these mutations might identify a biologically specific subgroup with the potential to progress to NEC. In addition to the nature of poorly differentiated NECs and their potential relationship to well-differentiated PanNETs, there has also been much speculation on the relationship of poorly differentiated NECs to PDAC. 17 One of the genetic changes frequently seen in ductal adenocarcinomas, loss of SMAD4/DPC4, was infrequently observed in poorly differentiated NECs in this study (1 of 19, 5%) . KRAS mutations, an almost uniform feature of PDAC, 16 was observed in only 2 of 7 poorly differentiated NECs (28%), suggesting that most poorly differentiated NECs do not arise from preexisting ductal lesions. Again, this does not entirely rule out the possibility that some PDACs may have given rise to coexistent poorly differentiated NECs, 17, 35 although this may be a relatively uncommon occurrence.
It is interesting to note that loss of Rb protein is frequently observed in other poorly differentiated NECs of the gallbladder 46 and small cell carcinomas of the ampulla of Vater. 38 These results suggest that inactivation of Rb protein is a characteristic molecular event in high-grade NECs in the gastrointestinal tract. Interestingly, in mouse models of human small cell lung carcinoma, Cre-mediated deletion of RB1 and TP53 conditional alleles in the lungs of adult mice results in the development of tumors that share many characteristics with human small cell lung carcinoma, including their histopathology, the expression of neuroendocrine markers, and their ability to metastasize. 33 Another experimental study demonstrated that conditional deletion of RB1 alone in mouse airway cells induced the proliferation of neuroendocrine cells. 52 Thus, combined loss of p53 and Rb function appears to be a necessary step for the development of this tumor, and alterations of the RB1 gene may play an important role in terms of manifestation of neuroendocrine features. 6, 24, 26 Interestingly, overexpression of Bcl-2 protein was observed in all 9 small cell NECs and in 50% of large cell NECs but in only 18% of well-differentiated PanNETs in the current study. Moreover, our data indicate that Bcl-2 overexpression may account for the relatively higher proliferation rate seen in the small cell NEC compared with the large cell NEC and in some G2 well-differentiated PanNETs compared with G1 tumors. Bcl-2 is a central apoptotic inhibitor, and overexpression of Bcl-2 protein is a characteristic finding in small cell lung carcinomas. 20 Chemotherapeutic agents, including platinum, have been shown to exert their cytotoxic effects by inducing apoptosis through the mitochondrial (or intrinsic) pathway regulated by Bcl-2. 23 Bcl-2 overexpression increases resistance to chemotherapy in both in vitro and in vivo models. 12, 49 Furthermore, high levels of Bcl-2 protein have been associated with neuroendocrine differentiation 1,20 and a more aggressive malignant phenotype. 22 It has been of considerable interest to assess the potential therapeutic synergy between Bcl-2 antagonists/ inhibitors and standard chemotherapies; in addition, several Bcl-2 antagonists/inhibitors, including obatoclax mesylate (GX15-070), are currently entering clinical trial in small cell lung carcinomas. 44 Thus, the finding of Bcl-2 protein overexpression in poorly differentiated NECs of the pancreas, irrespective of small or large cell morphology, suggests that Bcl-2 antagonists/inhibitors might be a viable treatment option to test for these patients.
The molecular abnormalities and median survival of small cell NEC, large cell NEC, well-differentiated PanNET, PDAC, and small cell lung carcinoma are summarized in Table 5 , based on the current study and previously published reports that include our own work. 4, 9, 10, 15, 18, 29, 34, 37, 51, 55 There is no consensus on the treatment of poorly differentiated NECs, specifically small cell NECs, of the pancreas at this time. 19 In our series, 6 of 8 (75%) patients with small cell NEC and 5 of 10 (50%) with large cell NEC and available information survived for at least 12 months, suggesting a potential role for surgery for limited disease. However, surgery alone is unlikely to be sufficient for the treatment of poorly differentiated NEC, because most patients in our series eventually died of recurrence or metastasis. Prospective randomized trials of therapy for this disease are unlikely in the future because of the rarity of the disease. Systemic therapies, including preoperative or postoperative chemotherapy with platinum agents, may be promising for the improvement of prognosis in patients with poorly differentiated NEC of the pancreas, even if the size of the primary cancer is small and the disease is limited. In support of this notion, among the 9 patients with poorly differentiated NEC in the current study with known treatment history, 5 received a cisplatin-based regimen as first-line or second-line treatment, and the median survival of these patients was 15 months. In contrast, the 4 patients who received alternative treatments had a median survival of 6 months. Thus, as the genetic alterations of small cell and large cell NECs of the pancreas are highly similar to those of small cell lung carcinoma, it may be reasonable to manage poorly differentiated NECs of the pancreas along broadly similar lines to other carcinomas with small cell morphology, as reported in highgrade NECs of other organs. 5 In conclusion, poorly differentiated NECs, represented by small cell and large cell NECs, are highly aggressive neoplasms with a dismal prognosis. We now show that small cell and large cell NECs are genetically similar to each other and are distinct from well-differentiated PanNET. Management of small and large cell NECs of the pancreas may benefit from therapeutic approaches that are broadly similar to those of small cell carcinomas arising in other organs.
